In vivo (Athens, Greece) · 2022
Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Serban Dragos, Costea Daniel Ovidiu, Zgura Anca, Tudosie Mihail Silviu, Dascalu Ana Maria, Gangura Gabriel Andrei, Smarandache Catalin Gabriel, Dan Sabau Alexandru, Tudor Corneliu, Faur Mihai, Costea Andreea Cristina, Stana Daniela, Balasescu Simona Andreea, Tribus Laura Carina, Tanasescu Ciprian
Аннотация
BACKGROUND: Aromatase inhibitor therapy is currently the preferred choice in postmenopausal women with estrogen receptor positive breast cancer. This article reviews the ocular side effects of treatment with aromatase inhibitors (AIs) in patients with breast cancer.
MATERIALS AND METHODS: A comprehensive search was performed on PubMed, Web of Science and Google scholar.
RESULTS: After duplication removal, 14 clinical studies and 5 case reports, published between 2008 and 2021, were identified. Most frequently, AI treatment resulted in minor to moderate dry eye symptoms. "De novo" onset of Sjogren syndrome during AI therapy was also reported. Retinal and optic nerve side effects varied from mild, subclinical anatomic and functional impairment to severe decreased vision, secondary to hemi-central retinal artery occlusion, bilateral optic neuritis or uveitis with bilateral macular edema.
CONCLUSION: Visual disturbances encountered during AI treatment may be underestimated. Ophthalmic screening is important for early detection and appropriate treatment.
MATERIALS AND METHODS: A comprehensive search was performed on PubMed, Web of Science and Google scholar.
RESULTS: After duplication removal, 14 clinical studies and 5 case reports, published between 2008 and 2021, were identified. Most frequently, AI treatment resulted in minor to moderate dry eye symptoms. "De novo" onset of Sjogren syndrome during AI therapy was also reported. Retinal and optic nerve side effects varied from mild, subclinical anatomic and functional impairment to severe decreased vision, secondary to hemi-central retinal artery occlusion, bilateral optic neuritis or uveitis with bilateral macular edema.
CONCLUSION: Visual disturbances encountered during AI treatment may be underestimated. Ophthalmic screening is important for early detection and appropriate treatment.